We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Open Drawer MenuClose Drawer Menu
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Nanoarchitectonics of doxycycline-loaded vitamin E–D-α-tocopheryl polyethylene glycol 1000 succinate micelles for ovarian cancer stem cell treatment

    Zoha Hajikhani

    Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Search for more papers by this author

    ,
    Ismaeil Haririan

    *Author for correspondence:

    E-mail Address: haririan@tums.ac.ir

    Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Institute of Biomaterials, University of Tehran & Tehran University of Medical Sciences (IBUTUMS), Tehran, Iran

    Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Search for more papers by this author

    ,
    Mohammad Akrami

    **Author for correspondence:

    E-mail Address: m-akrami@sina.tums.ac.ir

    Department of Pharmaceutical Biomaterials & Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

    Institute of Biomaterials, University of Tehran & Tehran University of Medical Sciences (IBUTUMS), Tehran, Iran

    Search for more papers by this author

    &
    Saba Hajikhani

    Department of Chemistry, Faculty of Physics & Chemistry, Alzahra University, Tehran, Iran

    Search for more papers by this author

    Published Online:13 Oct 2023https://doi.org/10.2217/nnm-2022-0274

    Abstract

    Aim: This study aim to develop doxycycline within the D-α-tocopheryl polyethylene glycol 1000 succinate micelle platform as an anticancer stem cell agent. Materials & methods: The optimized nanomicelle formulation was prepared using the solvent casting method and evaluated through physicochemical and biological characterization. Results: Nanomicelles exhibited mean particle sizes of 14.48 nm (polydispersity index: 0.22) using dynamic light scattering and 18.22 nm using transmission electron micrography. Drug loading and encapsulation efficiency were 2% and 66.73%, respectively. Doxycycline-loaded micelles exhibited sustained release, with 98.5% released in 24 h. IC50 values were 20 μg/ml for free drug and 5 μg/ml for micelles after 48 h of cell exposure. A significant 74% reduction in CD44 biomarker and 100% colony formation inhibition were observed. Conclusion: Doxycycline in hemo/biocompatible nanomicelles holds potential for ovarian cancer stem cell therapy.

    Plain language summary

    Cancer, a global leading cause of death, has a significant impact on human health. Among the various types of cancer, ovarian cancer ranks as the seventh most prevalent, posing a significant threat to women and contributing significantly to deaths in this population. Recent studies have highlighted the importance of targeting cancer stem cells to enhance the effectiveness of cancer treatments and prevent tumor relapse. Cancer stem cells are cells that can differentiate into different cell types in a tumor, driving the growth and spread of cancer. Over the past few decades, certain antibiotics, including doxycycline, have emerged as potent and selective anticancer stem cell agents by specifically targeting mitochondrial biogenesis. In line with this, the authors developed a doxycycline-loaded micelle delivery system. Micelles are spheres made of a single layer of a type of fat called phospholipids; they have been combined with drugs to increase the successful delivery and effectiveness of that drug. This research revealed that this micelle formulation demonstrated a fourfold increase in efficacy against ovarian cancer stem cells compared with free antibiotics. Moreover, it efficiently reduced colony formation and CD44 biomarker levels among the stem cells, indicating damage to cancer stem cells. These findings underscore the potential of this doxycycline-loaded micelle system as a promising approach for eradicating ovarian cancer stem cells and improving therapeutic outcomes.

    Graphical abstract

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Keyvani V, Farshchian M, Esmaeili S-A et al. Ovarian cancer stem cells and targeted therapy. J. Ovarian Res. 12(1), 120 (2019).
      MedlineGoogle Scholar
    • 2. Yang W, Kim D, Kim DK, Choi KU, Suh DS, Kim JH. Therapeutic strategies for targeting ovarian cancer stem cells. Int. J. Mol. Sci. 22(10), 5059 (2021).
      Medline CASGoogle Scholar
    • 3. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin. Oncol. Nurs. 35(2), 151–156 (2019).
      MedlineGoogle Scholar
    • 4. Terraneo N, Jacob F, Dubrovska A, Grünberg J. Novel therapeutic strategies for ovarian cancer stem cells. Front. Oncol. 10 (2020).
      MedlineGoogle Scholar
    • 5. Torre LA, Trabert B, Desantis CE et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68(4), 284–296 (2018).
      MedlineGoogle Scholar
    • 6. Pieterse Z, Amaya-Padilla MA, Singomat T et al. Ovarian cancer stem cells and their role in drug resistance. Int. J. Biochem. Cell Biol. 106, 117–126 (2019).
      Medline CASGoogle Scholar
    • 7. Jin X, Jin X, Kim H. Cancer stem cells and differentiation therapy. Tumour Biol. 39(10), 1010428317729933 (2017).
      Google Scholar
    • 8. Yang L, Shi P, Zhao G et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target. Ther. 5(1), 8 (2020).
      MedlineGoogle Scholar
    • 9. Garcia-Mayea Y, Mir C, Masson F, Paciucci R, Me LL. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin. Cancer Biol. 60, 166–180 (2020).
      Medline CASGoogle Scholar
    • 10. Lamb R, Fiorillo M, Chadwick A et al. Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: implications for more effective radiation therapy. Oncotarget 6(16), 14005–14025 (2015).
      MedlineGoogle Scholar
    • 11. Fiorillo M, Tóth F, Sotgia F, Lisanti MP. Doxycycline, azithromycin and vitamin C (DAV): a potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs). Aging (Albany NY) 11(8), 2202–2216 (2019).
      Medline CASGoogle Scholar
    • 12. De Francesco EM, Maggiolini M, Tanowitz HB, Sotgia F, Lisanti MP. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for optimizing anti-angiogenic therapy. Oncotarget 8(34), 56126–56142 (2017).
      MedlineGoogle Scholar
    • 13. Bartakova A, Michalova K, Presl J, Vlasak P, Kostun J, Bouda J. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma. J. Obstet. Gynaecol. 38(1), 110–114 (2018).
      Medline CASGoogle Scholar
    • 14. Lin J, Ding D. The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis. Cancer Cell Int. 17, 8 (2017).
      MedlineGoogle Scholar
    • 15. Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int. 2016, 2087204 (2016). • Helped the authors select CD44 as a surface marker of cancer stem cells.
      MedlineGoogle Scholar
    • 16. Al-Alem LF, Pandya UM, Baker AT et al. Ovarian cancer stem cells: what progress have we made? Int. J. Biochem. Cell Biol. 107, 92–103 (2019).
      Medline CASGoogle Scholar
    • 17. Andrade F, Rafael D, Vilar-Hernández M et al. Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. J. Control. Rel. 331, 198–212 (2021).
      Medline CASGoogle Scholar
    • 18. Yadav D, Dewangan HK. PEGYLATION: an important approach for novel drug delivery system. J. Biomater. Sci. Polym. Ed. 32(2), 266–280 (2021).
      Medline CASGoogle Scholar
    • 19. Kumbhar PS, Nadaf S, Manjappa AS et al. D-α-tocopheryl polyethylene glycol succinate: a review of multifarious applications in nanomedicines. OpenNano 6, 100036 (2022).
      Google Scholar
    • 20. Tavares Luiz M, Delello Di Filippo L, Carolina Alves R et al. The use of TPGS in drug delivery systems to overcome biological barriers. Eur. Polym. J. 142, 110129 (2021).
      Google Scholar
    • 21. Bernabeu E, Gonzalez L, Cagel M, Gergic EP, Moretton MA, Chiappetta DA. Novel Soluplus(®)-TPGS mixed micelles for encapsulation of paclitaxel with enhanced in vitro cytotoxicity on breast and ovarian cancer cell lines. Colloids Surf. B Biointerfaces 140, 403–411 (2016).
      Medline CASGoogle Scholar
    • 22. Muthu MS, Kulkarni SA, Liu Y, Feng SS. Development of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in rats. Nanomedicine (Lond.) 7(3), 353–364 (2012). • Helped the authors develop the D-α-tocopheryl polyethylene glycol 1000 succinate micelle form.
      CASGoogle Scholar
    • 23. Tyrrell ZL, Shen Y, Radosz M. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog. Polym. Sci. 35(9), 1128–1143 (2010).
      CASGoogle Scholar
    • 24. Akrami M, Balalaie S, Hosseinkhani S et al. Tuning the anticancer activity of a novel pro-apoptotic peptide using gold nanoparticle platforms. Sci. Rep. 6(1), 31030 (2016).
      Medline CASGoogle Scholar
    • 25. Lu Y, Ma W, Mao J et al. Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of Hedgehog signaling. Chem. Biol. Interact. 228, 100–107 (2015).
      Medline CASGoogle Scholar
    • 26. Lamb R, Ozsvari B, Lisanti CL et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. Oncotarget 6(7), 4569–4584 (2015). • The main article that interested the authors aims to enhance the efficacy of doxycycline in eradicating cancer stem cells.
      MedlineGoogle Scholar
    • 27. Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine 11(6), 673–692 (2016).
      CASGoogle Scholar
    • 28. Danaei M, Dehghankhold M, Ataei S et al. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics 10(2), 57 (2018).
      MedlineGoogle Scholar
    • 29. Mahajan HS, Patil PH. Central composite design-based optimization of lopinavir vitamin E-TPGS micelle: in vitro characterization and in vivo pharmacokinetic study. Colloids Surf. B Biointerfaces 194, 111149 (2020). •• Assisted the authors in conducting the optimization process.
      Medline CASGoogle Scholar
    • 30. Wang S, Liu R, Fu Y, Kao WJ. Release mechanisms and applications of drug delivery systems for extended-release. Expert Opin. Drug Deliv. 17(9), 1289–1304 (2020).
      Medline CASGoogle Scholar
    • 31. Scatena C, Roncella M, Di Paolo A et al. Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: a clinical pilot study. Front. Oncol. 8, 452 (2018).
      MedlineGoogle Scholar
    • 32. Rajendran V, Jain MV. In vitro tumorigenic assay: colony forming assay for cancer stem cells. In: Cancer Stem Cells: Methods and Protocols. Papaccio GDesiderio V (Eds). Springer New York, NY, USA, 89–95 (2018).
      Google Scholar